Clinical trials: Emphysema, Pulmonary
Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
This is a multicenter, parallel-group, double-blind, randomized phase 4 study designed to identify the optimal dose of CE1226 (2 active doses) to slow disease progression as assessed by reduced rates of annual lung density…
- Conditions
- Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema
- Trial name
- NCT07326592
- Testing
- CE1226
- Where
- 2 sites in Denmark
- Volunteers
- 270 people
- Sponsor
- CSL Behring
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
This study is evaluating the effectiveness of a dose counter for an inhaler device used to deliver medication to people diagnosed with asthma or COPD.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
- Trial name
- NCT01302587
- Testing
- Albuterol
- Where
- 25 sites in United States
- Volunteers
- 306 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Alpha-1 Antitrypsin Deficiency (AATD)
A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
This is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults…
- Trial name
- NCT07227207
- Testing
- TSRA-196
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 72 people
- Sponsor
- Tessera Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Identifying REsponders and Exploring Mechanisms of ACTION of the Endobronchial Coil Treatment for Emphysema
Rationale: The PneumRx RePneu Lung Volume Reduction Coil (RePneu LVR-coil) is a bronchoscopic lung volume reduction treatment designed to compress the areas of lung parenchyma most damaged by emphysema.
- Trial name
- REACTION (NCT02179125)
- Testing
- RePneu Lung Volume Reduction Coil System
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 48 people
- Sponsor
- University Medical Center Groningen
Emphysema
Spiration Valve System 9 mm European Post Market Evaluation Study
The purpose of this observational study is to investigate the efficacy of 9 mm intrabronchial valve treatment in patients with heterogeneous emphysema and to gain further insights and experience on the treatment with this valve…
- Trial name
- NCT03008226
- Testing
- Implementation of 9 mm intrabronchial valves
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Cardiovascular Diseases, Coronary Disease
Honolulu Heart Program
To investigate coronary heart disease and stroke among American men of Japanese ancestry who were living on the island of Oahu in 1965. Morbidity and mortality surveillance of the original cohort is continuing.
- Conditions
- Cardiovascular Diseases, Coronary Disease, Cerebrovascular Accident, Heart Diseases
- Trial name
- NCT00005123
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
COPD
A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world.
- Trial name
- NCT01794780
- Testing
- LABA based treatment: indacaterol, LAMA based treatment: tiotropium, LABA/ICS based treatment: salmeterol/fluticasone
- Where
- 2 sites in China
- Volunteers
- 2,229 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Pulmonary Disease, Chronic Obstructive
Advancing Symptom Alleviation With Palliative Treatment
Chronic heart failure (CHF), chronic obstructive pulmonary disease (COPD), and interstitial lung disease (i.e., pulmonary fibrosis) are common serious illnesses.
- Conditions
- Heart Failure, Pulmonary Disease, Chronic Obstructive, Emphysema, Pulmonary Fibrosis, Interstitial Lung Disease
- Trial name
- ADAPT (NCT02713347)
- Testing
- ADAPT Intervention
- Where
- 2 sites in United States
- Volunteers
- 306 people
- Sponsor
- VA Office of Research and Development
Moderate COPD
Endobronchial Valves in Moderate COPD
Despite the best medical therapy many people with emphysema remain breathless and limited in their daily activities. In emphysema the lungs do not empty properly when the person breathes out.
- Trial name
- REMODEL (NCT01969734)
- Testing
- Zephyr endobronchial valve placement
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Sherwood Forest Hospitals NHS Foundation Trust
Alpha-1 Antitrypsin Deficiency (AATD)
Effect Of Pulmonary Rehabilitation in Patients With Alpha-1 Antitrypsin Deficiency
This single-center, longitudinal, observational, prospective study aims to assess the applicability, adherence, and clinical impact of the Active Cycle of Breathing Technique (ACBT) with augmented reality support in patients with…
- Trial name
- RRALFA1 (NCT07242079)
- Testing
- Pulmonary Rehabilitation
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Parma
Chronic Obstructive Pulmonary Disease, Bronchitis
Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- Trial name
- NCT00250679
- Testing
- Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID
- Where
- 60 sites in United States
- Volunteers
- 443 people
- Sponsor
- Sumitomo Pharma America, Inc.
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
- Trial name
- NCT00683722
- Testing
- Prochymal™
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- Mesoblast, Inc.
Alpha1-Antitrypsin Deficiency
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-alpha-1 antitrypsin (Z-AAT) protein.
- Trial name
- NCT05899673
- Testing
- Fazirsiran Injection
- Where
- 10 sites in United States, Austria and 3 more
- Volunteers
- 31 people
- Sponsor
- Takeda
Lung Neoplasms, Emphysema
Computed Tomography Assessment of Regional Ventilation (CURVE)
This study uses CT scans to assess airflow in the lung, the scan is quick, cheap and painless. The information from the scan may help doctors tell which patients are suitable to have surgery to cure early stage lung cancer.
- Conditions
- Lung Neoplasms, Emphysema, Lung Diseases, Interstitial, Pulmonary Disease, Chronic Obstructive
- Trial name
- CURVE (NCT02879773)
- Testing
- CTPVe
- Where
- United Kingdom
- Volunteers
- 131 people
- Sponsor
- Heart of England NHS Trust
Alpha-1-antitrypsin Deficiency, Liver Cirrhosis
Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency
The primary objective is to determine if the medication Carbamazepine, can be used as a therapy for patients with severe liver disease due to Alpha-1-Antitrypsin Deficiency .
- Trial name
- CBZ (NCT01379469)
- Testing
- Drug-Carbamazepine (Tegretol XR)
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Alpha 1-Antitrypsin Deficiency
The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency
The objective of this study is to prospectively assess whether there is any interval between first symptom and initial diagnosis that is experienced by patients with newly diagnosed alpha-1 antitrypsin deficiency (AATD) and then…
- Trial name
- NCT03039335
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Biocerna LLC
Advanced Emphysema
A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema
This is a multi-center, open-label, non-controlled Pilot Study. Approximately 24 patients will be assigned to one of 3 treatment groups (8 patients each group).
- Trial name
- NCT00884962
- Testing
- Polymeric Lung Volume Reduction System (PLVR)
- Where
- 6 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Aeris Therapeutics
COPD, Heterogeneous Emphysema
To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves
To compare the clinical outcomes of Endoscopic Lung Volume Reduction (ELVR) using Pulmonx Zephyr Valves vs. Standard of Care (SoC) in the treatment of heterogeneous emphysema subjects in a controlled trial design setting.
- Trial name
- TRANSFORM (NCT02022683)
- Testing
- ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 97 people
- Sponsor
- Pulmonx Corporation
Alpha-1 Antitrypsin Deficiency
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose…
- Trial name
- NCT06405633
- Testing
- WVE-006
- Where
- 9 sites in Australia, Canada and 4 more
- Volunteers
- 48 people
- Sponsor
- Wave Life Sciences USA, Inc.
Alpha 1-Antitrypsin Deficiency
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
The purpose of this study is to evaluate the the safety and efficacy of the investigational product, fazirsiran (TAK-999, ARO-AAT), administered subcutaneously to patients with alpha-1 antitrypsin deficiency associated liver…
- Trial name
- NCT03946449
- Testing
- ARO-AAT
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 16 people
- Sponsor
- Arrowhead Pharmaceuticals